GB1131931A - Improvements in and relating to vaccines - Google Patents

Improvements in and relating to vaccines

Info

Publication number
GB1131931A
GB1131931A GB43577/64A GB4357764A GB1131931A GB 1131931 A GB1131931 A GB 1131931A GB 43577/64 A GB43577/64 A GB 43577/64A GB 4357764 A GB4357764 A GB 4357764A GB 1131931 A GB1131931 A GB 1131931A
Authority
GB
United Kingdom
Prior art keywords
virus
vaccine
strain
foot
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB43577/64A
Inventor
Ronald David Ferris
Thomas William Ferran Pay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANIMAL VIRUS RES INST
Wellcome Foundation Ltd
Original Assignee
ANIMAL VIRUS RES INST
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANIMAL VIRUS RES INST, Wellcome Foundation Ltd filed Critical ANIMAL VIRUS RES INST
Priority to GB43577/64A priority Critical patent/GB1131931A/en
Priority to ES0318842A priority patent/ES318842A1/en
Priority to DE19651492254 priority patent/DE1492254A1/en
Priority to BR174354/65A priority patent/BR6574354D0/en
Publication of GB1131931A publication Critical patent/GB1131931A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1,131,931. Vaccine for foot and mouth disease. WELLCOME FOUNDATION Ltd. and ANIMAL VIRUS RESEARCH INSTITUTE. 21 Oct., 1965 [26 Oct., 1964], No. 43577/64. Heading A5B. [Also in Division C6] A vaccine for preventing foot-and-mouth disease Type A comprises a homogenous, non- virulent immunogenic strain of foot-and-mouth virus Type A in a therapeutically acceptable vehicle, the virus being produced by cloning on a baby hamster kidney cell (BHK21) monolayer culture, a heterogeneous Type A strain of the virus which has been modified by about 45 serial passages in chick embryos (e.g. the Kemron egg strain), so as to produce plaques originating from a single virus particle, selecting plaques according to their conformity in size, and further cloning on BHK21 monolayer cultures until homogeneity of plaque size is achieved, and selecting and separating the strain which shows negligible virulence with sufficient immunogenicity on testing. The virus is then propagated in intact animals or chick embryos, primary culture of animal tissue, or a secondary culture of susceptible cells. After removal of cell debris, the harvested liquid may be used as such as a vaccine, or concentrated if necessary, suitably by the method of Specification 1,058,081, or freeze-dried and reconstituted with a buffered glycerol solution containing a virus stabiliser. Preferably after the virus has been applied to the BHK monolayer, the latter is washed with a slightly acidic (e.g. pH 5.5-6.5) aqueous buffer solution, such as acetate buffer or phosphate buffer saline. The invention includes a method for preventing or treating foot-and-mouth Type A disease in animals, by immunising with the vaccine. Reference has been directed by the Comptroller to Specification 1,015,262.
GB43577/64A 1964-10-26 1964-10-26 Improvements in and relating to vaccines Expired GB1131931A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB43577/64A GB1131931A (en) 1964-10-26 1964-10-26 Improvements in and relating to vaccines
ES0318842A ES318842A1 (en) 1964-10-26 1965-10-23 A method for the production of a new non-virginal, immunogenic and homogeneous virus of glosopeda type a. (Machine-translation by Google Translate, not legally binding)
DE19651492254 DE1492254A1 (en) 1964-10-26 1965-10-25 Improvements in and relating to vaccines
BR174354/65A BR6574354D0 (en) 1964-10-26 1965-10-26 PROCESS FOR THE PRODUCTION OF A NEW IMMUNOGENIC AND HOMOGENEOUS NON-VIRULENT LINES OF VIRUS, TYPE A,

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB43577/64A GB1131931A (en) 1964-10-26 1964-10-26 Improvements in and relating to vaccines

Publications (1)

Publication Number Publication Date
GB1131931A true GB1131931A (en) 1968-10-30

Family

ID=10429373

Family Applications (1)

Application Number Title Priority Date Filing Date
GB43577/64A Expired GB1131931A (en) 1964-10-26 1964-10-26 Improvements in and relating to vaccines

Country Status (4)

Country Link
BR (1) BR6574354D0 (en)
DE (1) DE1492254A1 (en)
ES (1) ES318842A1 (en)
GB (1) GB1131931A (en)

Also Published As

Publication number Publication date
DE1492254A1 (en) 1969-11-20
ES318842A1 (en) 1967-03-01
BR6574354D0 (en) 1973-08-16

Similar Documents

Publication Publication Date Title
Rockborn Canine distemper virus in tissue culture
Leung et al. Cells mediating delayed‐type hypersensitivity in the lungs of mice infected with an influenza A virus
US3959466A (en) Highly attenuated cytomegalovirus vaccine and production thereof
ES336810A1 (en) Feline virus vaccines obtained by propagation and serial passage attenuation of virulent feline viruses in diploid feline embryo tissue cell serial passage subculture strains
Harmon et al. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines
Magill et al. Studies with human influenza virus cultivated in artificial medium
US3080291A (en) Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom
US4571386A (en) Feline infectious peritonitis vaccine
Brown et al. In vitro measurement of the potency of inactivated foot-and-mouth disease virus vaccines
US4320115A (en) Rabies virus vaccine
US4034081A (en) Vaccines against feline leukemia
CA1039187A (en) Feline leukemia vaccines
US4322404A (en) Process for the production of new mutants of herpes simplex virus type 1 and type 2
US4980162A (en) Live vaccine for contagious diseases of chickens
US3479430A (en) Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same
GB1131931A (en) Improvements in and relating to vaccines
US4335105A (en) Specific antigen vaccine for TGE in swine
Ramyar Studies on the Immunogenic Properties of Tissue‐Culture Sheep Pox Virus
US3585108A (en) Transmissible gastroenteritis vaccines and methods of producing the same
US3704203A (en) Transmissible gastroenteritis vaccines and methods of producing the same
EP0028804B1 (en) Vaccine and method for its preparation
US4255520A (en) Process for the preparation of a rabies vaccine and vaccine obtained by this process
US3725542A (en) Intramuscular vaccination program and vaccine against rhinopneumonitis and process for preparing it
Russell Malignant catarrhal fever virus in rabbits—reproduction of clinical disease by cell-free virus and partial protection against such disease by vaccination with inactivated virus
Kaminjolo Jr et al. Isolation, cultivation and characterization of a poxvirus from some horses in Kenya